Carcinoma Transitional Cell
📧 Sign up to get email alerts when something new happens for Carcinoma Transitional Cell.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-29EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.
EMA authorizes Padcev (enfortumab vedotin) for specified urologic carcinoma indications, marking an official market approval.
-
EMA approval · 2026-07-22EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.
The EMA authorised Padcev (enfortumab vedotin) for indicated urologic cancers, marking a new approval by Astellas Pharma Europe B.V.
-
EMA approval · 2026-06-25EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.
EMA authorised Padcev (enfortumab vedotin) for conditions within transitional cell carcinoma and urologic neoplasms.